WAM
AVBP icon

Weiss Asset Management’s ArriVent BioPharma AVBP Stock Holding History

Weiss Asset Management’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-53,786
Closed -$1.17M – 809
2025
Q2 		$1.17M Buy
+53,786
New +$1.12M 0.01% 315

Other funds holding AVBP

HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Weiss Asset Management's AVBP Position: Q3 2025 in Review

Weiss Asset Management sold out of ArriVent BioPharma (AVBP) in Q3 2025, closing a stake of 53,786 shares — an estimated $1.17M sold.

Weiss Asset Management first reported a position in AVBP in Q2 2025 and held it in 1 quarter. The position peaked at $1.17M in Q2 2025. 106 funds tracked by Wall St. Rank hold AVBP as of Q3 2025.

  • Weiss Asset Management reported no remaining ArriVent BioPharma position as of Q3 2025 after selling out during the quarter.
  • Weiss Asset Management sold 53,786 ArriVent BioPharma shares in Q3 2025, an estimated $1.17M.
  • Weiss Asset Management first reported a position in ArriVent BioPharma in Q2 2025 and held it in 1 quarter.
  • Weiss Asset Management's ArriVent BioPharma position peaked at $1.17M in Q2 2025.
  • 106 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q3 2025.

Based on Weiss Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.